New York’s legal cannabis market, which is still in its infancy, will undergo major changes that could allow for the sale of hemp-based products to be sold in dispensaries and also give out-of state operators the opportunity to operate.
The New York Senate introduced a bill on March 3rd that would eliminate the July enforcement date for the Emergency Regulations restricting the sales of intoxicating products made from hemp.
While the federal government has little or no legislation on intoxicating hemp, states continue to introduce their own laws to regulate this poorly-researched and new set of substances.
New York’s Office for Cannabis Management had passed emergency regulations in order to stop the proliferation of such products. These included THC-based variants, like Delta 10 or Delta 8. The regulation was set to take effect on July 27th 2025.
S05809 was submitted by the New York State Senate to end this clampdown. It focuses specifically on Delta 9 THC – the psychoactive compound found in marijuana – and may allow the sale of THC derivatives from other licensed dispensaries.
Licensed cannabis retailers will be able to legally sell hemp-derived cannabinoids beginning in 2026, as long as they comply with safety standards established by OCM.
While the OCM introduced the new Adult-Use Processor Type 3 Branding License this week, it offers a way for brands of cannabis to access the New York legal cannabis market, without the need to run a physical facility or touch plants directly.
The New York cannabis programme, which was created to encourage local business and stop giant operators from entering the market by force of will, could be removed.
Type 3 Branding Licenses enable a cannabis company to promote its products on the New York market through agreements between state licensed processors and white label brands.
Under this arrangement, a licensed processor handles all cannabis-related activities—including extraction, blending, infusion, packaging, and labelling—while the brand licensee contributes intellectual property (such as logos and product specifications) and non-cannabis materials (like rolling papers, flavouring agents, or vaporizers). To ensure consistency, the processor must adhere to brand-specific quality standards established by the licensee.
Importantly, this license allows brands to enter the New York market without being classified as a ‘True Party of Interest’ in a processing facility, making it easier for companies to expand without direct financial or operational entanglements with New York-based processors.
The New York Office of Cannabis Management still demands full disclosure of all ownership, financial, and management details in order to comply with the regulations regarding ownership limits, influence, and control.
New York’s legal cannabis market, which is still in its infancy, will undergo major changes that could allow for the sale of hemp-based products to be sold in dispensaries and also give out-of state operators the opportunity to operate.
The New York Senate introduced a bill on March 3rd that would eliminate the July enforcement date for the Emergency Regulations restricting the sales of intoxicating products made from hemp.
Individual states have continued to introduce legislation as the intoxicating hemp march continues to spread across the nation, despite the fact that federal law does not regulate it.
New York’s Office for Cannabis Management had passed emergency regulations in order to stop the proliferation of such products. These included THC-based variants, like Delta 10 or Delta 8. The regulation was set to take effect on July 27th 2025.
S05809 was submitted by the New York State Senate to end this clampdown. It focuses specifically on Delta 9 THC – the psychoactive compound found in marijuana – and may allow the sale of THC derivatives from other licensed dispensaries.
Licensed cannabis retailers will be able to legally sell hemp-derived cannabinoids beginning in 2026, as long as they comply with safety standards established by OCM.
While the OCM introduced the new Adult-Use Processor Type 3 Branding License this week, it offers a way for brands of cannabis to access the New York legal cannabis market, without the need to run a processing plant or touch plants directly.
The New York cannabis programme, which was created to encourage local business and stop giant operators from entering the market by force of will, could be removed.
Type 3 Branding License is a license that allows a cannabis company to promote its product in New York via white label agreements with licensed state processors.
Under this arrangement, a licensed processor handles all cannabis-related activities—including extraction, blending, infusion, packaging, and labelling—while the brand licensee contributes intellectual property (such as logos and product specifications) and non-cannabis materials (like rolling papers, flavouring agents, or vaporizers). To ensure consistency, the processor must adhere to brand-specific quality standards established by the licensee.
Importantly, this license allows brands to enter the New York market without being classified as a ‘True Party of Interest’ in a processing facility, making it easier for companies to expand without direct financial or operational entanglements with New York-based processors.
New York Office of Cannabis Management requires that all financial and ownership details be disclosed to the office in order for it to adhere with its regulations regarding control, ownership limitations, and any undue influences.
Cannabis Law Resources in Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. These guides will help you understand the legal requirements, such as certification and permissions.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland